---
schema_version: "secwatch.filing_event.v1"
accession: "0001522767-24-000063"
form_type: "8-K"
ticker: "MRMD"
cik: "0001522767"
company_name: "MARIMED INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:43:25.062948+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MariMed Q2 2024 revenue $40.4M, GAAP net loss $1.6M, adjusted EBITDA $4.4M

## Summary
- Revenue $40.4M, up 10.7% YoY from $36.5M; gross margin 42% (GAAP), 43% (non-GAAP).
- GAAP net loss $1.6M vs loss $0.9M in Q2 2023; non-GAAP net loss $0.2M vs income $0.6M.
- Non-GAAP adjusted EBITDA $4.4M (11% margin), down from $6.3M (17% margin) a year ago.
- Retail transactions increased 24% YoY; wholesale segment led overall growth.
- Management reaffirms 2024 financial targets; expects margin expansion and improved cash flow.

## SEC filing metadata
- accession: 0001522767-24-000063
- form_type: 8-K
- ticker: MRMD
- cik: 0001522767
- company_name: MARIMED INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1522767/000152276724000063/0001522767-24-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1522767/000152276724000063/mrmd-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001522767-24-000063
- JSON: https://secwatch.observer/filing/0001522767-24-000063.json
- Plain text: https://secwatch.observer/filing/0001522767-24-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.